688265 南模生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.5301.8530.380-1.175-0.304
总资产报酬率 ROA (%)0.4561.6070.331-1.016-0.269
投入资产回报率 ROIC (%)0.4851.6890.344-1.056-0.280

边际利润分析
销售毛利率 (%)54.51251.68945.63942.37841.744
营业利润率 (%)3.4047.1230.731-8.130-5.404
息税前利润/营业总收入 (%)4.6847.3971.001-7.195-5.618
净利润/营业总收入 (%)3.9057.4671.704-5.615-1.782

收益指标分析
经营活动净收益/利润总额(%)35.85350.351-643.137132.267226.040
价值变动净收益/利润总额(%)105.59466.862745.553-60.227-123.878
营业外收支净额/利润总额(%)-0.737-3.048-2.1750.342-11.260

偿债能力分析
流动比率 (X)5.0415.4696.5556.4797.471
速动比率 (X)4.8895.3836.4836.3917.369
资产负债率 (%)13.93813.83112.76913.06414.012
带息债务/全部投入资本 (%)5.3655.4335.3495.4585.177
股东权益/带息债务 (%)1,707.8611,683.0691,697.5671,654.9621,726.534
股东权益/负债合计 (%)617.444623.030683.158665.472613.699
利息保障倍数 (X)3.59015.2393.506-7.4747.381

营运能力分析
应收账款周转天数 (天)107.43195.979103.94598.54487.968
存货周转天数 (天)44.63627.77524.75128.06432.751